Uganda to receive over 94,000 doses of long-acting HIV prevention drug

By The Inspirer.

The Government of Uganda has announced it will receive more than 94,000 doses of the long-acting HIV prevention drug, Lenacapavir Yeztugo, marking a significant step in strengthening the country’s national response to HIV.

According to officials, 94,560 doses are expected to arrive next week as part of expanded efforts to scale up access to innovative prevention tools. The injectable drug is administered twice a year, offering a more convenient alternative to existing prevention methods.

Developed by US-based biopharmaceutical firm Gilead Sciences, Lenacapavir Yeztugo has shown exceptional efficacy in clinical trials conducted across several countries. Studies indicate that when administered every six months, the drug reduces the risk of HIV infection by up to 99.9 percent.

Uganda’s move follows a similar rollout in Kenya, which on February 17 received 21,000 doses of the same medication, signaling growing regional momentum toward long-acting HIV prevention solutions.

In July 2025, the World Health Organization approved Lenacapavir for use, describing it as a breakthrough in HIV prevention. Unlike post-exposure prophylaxis (PEP), which must be taken within 72 hours after potential exposure, or other injectable options administered every two months, this new regimen requires only two doses per year.

Health authorities say the introduction of the drug could significantly enhance adherence, reduce new infections, and accelerate progress toward ending HIV as a public health threat.